Cited by 75Gut microbiota and healthTryptophan and brain disordersTreatment of Major Depression

Gut microbiome-linked metabolites in the pathobiology of major depression with or without anxiety-a role for bile acids

Open access
MahmoudianDehkordi, Siamak, Bhattacharyya, Sudeepa, Brydges, Christopher R., Jia, Wei, Fiehn, Oliver, Rush, A. John, Dunlop, Boadie W., Kaddurah-Daouk, Rima·2022·Frontiers in Neuroscience

Abstract

Background The gut microbiome may play a role in the pathogenesis of neuropsychiatric diseases including major depressive disorder (MDD). Bile acids (BAs) are steroid acids that are synthesized in the liver from cholesterol and further processed by gut-bacterial enzymes, thus requiring both human and gut microbiome enzymatic processes in their metabolism. BAs participate in a range of important host functions such as lipid transport and metabolism, cellular signaling and regulation of energy homeostasis. BAs have recently been implicated in the pathophysiology of Alzheimer's and several other neuropsychiatric diseases, but the biochemical underpinnings of these gut microbiome-linked metabolites in the pathophysiology of depression and anxiety remains largely unknown. Method Using targeted metabolomics, we profiled primary and secondary BAs in the baseline serum samples of 208 untreated outpatients with MDD. We assessed the relationship of BA concentrations and the severity of depressive and anxiety symptoms as defined by the 17-item Hamilton Depression Rating Scale (HRSD 17 ) and the 14-item Hamilton Anxiety Rating Scale (HRSA-Total), respectively. We also evaluated whether the baseline metabolic profile of BA informs about treatment outcomes. Results The concentration of the primary BA chenodeoxycholic acid (CDCA) was significantly lower at baseline in both severely depressed (log 2 fold difference (LFD) = −0.48; p = 0.021) and highly anxious (LFD = −0.43; p = 0.021) participants compared to participants with less severe symptoms. The gut bacteria-derived secondary BAs produced from CDCA such as lithocholic acid (LCA) and several of its metabolites, and their ratios to primary BAs, were significantly higher in the more anxious participants (LFD's range = [0.23, 1.36]; p 's range = [6.85E-6, 1.86E-2]). The interaction analysis of HRSD 17 and HRSA-Total suggested that the BA concentration differences were more strongly correlated to the symptoms of anxiety than depression. Significant differences in baseline CDCA (LFD = −0.87, p = 0.0009), isoLCA (LFD = −1.08, p = 0.016) and several BA ratios (LFD's range [0.46, 1.66], p 's range [0.0003, 0.049]) differentiated treatment failures from remitters. Conclusion In patients with MDD, BA profiles representing changes in gut microbiome compositions are associated with higher levels of anxiety and increased probability of first-line treatment failure. If confirmed, these findings suggest the possibility of developing gut microbiome-directed therapies for MDD characterized by gut dysbiosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnins.2022.937906

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In patients with depression and anxiety, bile acid profiles associated with altered gut microbiota composition are significantly different in those with more severe symptoms.

    “In a study of patients with depression and anxiety, BA profiles associated with altered GM composition were significantly different in those with more severe symptoms, and specific BA parameters were able to distinguish treatment failures from remitters (330).”
  • Specific bile acid parameters can distinguish treatment failures from remitters in patients with depression and anxiety.

    “In a study of patients with depression and anxiety, BA profiles associated with altered GM composition were significantly different in those with more severe symptoms, and specific BA parameters were able to distinguish treatment failures from remitters (330).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 85 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. First M. B. S. Gibbon R. L. Williams J. B. W. (1995). Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Edition (SCID-I/P, version 2, 0.). New York, NY: Biometrics Research Department, New York State Psychiatric Institute.

Cited by

Sorted by citations

Authors
MahmoudianDehkordi, S., Bhattacharyya, S., Brydges, C. R., Jia, W., Fiehn, O., Rush, A. J., Dunlop, B. W., & Kaddurah-Daouk, R.
Affiliations
  • Duke University (US)
  • Arkansas State University (US)
  • University of California, Davis (US)
  • Hong Kong Baptist University (HK)
  • Texas Tech University (US)
  • Emory University (US)
Corresponding author
  • Dunlop, Boadie W.
  • Kaddurah-Daouk, Rima
Venue
Frontiers in Neuroscience
Published
2022-07-20
Volume
16
Pages
937906-937906
ISSN
1662-453X (ISSN-L)
OpenAlex
W4286208770
Cited by
75
References
85
Citations by year
2026: 19 · 2025: 16 · 2024: 26 · 2023: 13 · 2022: 1
FWCI
4.55
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
National Institutes of Health
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
major depressive disorder, anxiety, bile acids, gut microbiota, chenodeoxycholic acid, lithocholic acid, secondary bile acids, primary bile acids, serum metabolomics, depression severity, anxiety levels, treatment response, antidepressant response, gut-brain axis, bile acid ratio, comorbid depression and anxiety, energy homeostasis, neuroinflammation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review